ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2513

The Effect of Alcohol on Disease Activity in Axial Spondyloarthritis

Sizheng Zhao1,2, Daniel Thong3, Stephen Duffield1, David Hughes3 and Nicola Goodson1,2, 1Musculoskeletal Biology 1 Department, University of Liverpool, Liverpool, United Kingdom, 2Aintree University Hospital, Liverpool, United Kingdom, 3University of Liverpool, Liverpool, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: alcohol use, Ankylosing spondylitis (AS), axial spondyloarthritis and quality of life, Disease Activity

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: There has been much interest in smoking as a modifiable risk factor for increased disease severity in rheumatic diseases. However, the effects of alcohol consumption remain unclear. Alcohol intake has been associated with increased disease susceptibility in psoriatic arthritis but also with reduced disease severity in rheumatoid arthritis. Its role in axial spondyloarthritis (axSpA) has not been studied in detail. The aim of this study was to explore whether alcohol consumption is associated with disease severity in axSpA.

Methods: Alcohol histories were obtained from axSpA patients meeting the ASAS criteria. Participants were categorised as current drinkers or non-drinkers. Quantity of intake was estimated using units per week with heavy consumption defined as >14 u/week. Disease activity (BASDAI, spinal pain, ASDAS) and functional impairment (BASFI) were compared between alcohol drinkers and non-drinkers, using multivariable linear models adjusting for age, gender, TNF inhibition therapy (TNFi), smoking, index of deprivation and self-reported anxiety and depression (A&D). Given their recognised link, interaction terms between alcohol and A&D were included in these models. Association between heavy alcohol consumption and disease severity was explored within drinkers using multivariable models with the above covariates.

Results: We studied 229 axSpA patients: 76% were male with mean age 46.5 (SD±13.8) years. A third were treated with TNFi. The median BASDAI was 5.7 [interquartile range (IQR) 3.3, 7.6] and BASFI 5.7 [IQR 3.3, 7.6]. ASDAS was available for 79% of patients with mean of 2.7 (SD±1.1). Ever-smoking was reported by 47% and A&D by 54%. Alcohol drinking was reported by 64%, with drinkers reporting median intake of 6 u/week [IQR 2 to 20]. Compared with non-drinkers, drinkers had lower BASDAI, ASDAS and BASFI (Table 1). There were no differences in disease severity between heavy and moderate drinkers. Stratified by smoking status, associations between alcohol and disease severity were stronger in never-smokers. There was a significant interaction between alcohol and A&D in smokers: drinkers had lower BASDAI and BASFI in the absence of A&D.

Conclusion: Alcohol consumption appears to be associated with reduced axSpA disease severity in this cross-sectional cohort. These associations were influenced by smoking status and A&D. This novel finding supports the need for further investigation to explore whether lifestyle modification could lead to better disease outcomes in axSpA.

 

Table 1. Multivariable linear models of association between alcohol-drinking and measures of disease activity.

ß coefficient (95%CI)  without interaction terms

ß coefficient (95%CI)

in never-smokers

ß coefficient (95%CI) in ever-smokers if A&D is absent

BASDAI

-0.80 (-1.47, -0.38)

-1.35 (-2.26, -0.45)

-1.68 (-3.28, -0.07)

ASDAS

-0.34 (-0.65, -0.03)

-0.51 (-0.93, -0.10)

-0.69 (-1.40, 0.01)

Spinal pain

-0.76 (-1.54, 0.02)

-1.70 (-2.74, -0.66)

-0.45 (-2.37, 1.46)

BASFI

-1.39 (-2.11, -0.67)

-2.22 (-3.18, -1.26)

-2.48 (-4.21, -0.75)

Total sample sizes for each regression model were 213 for BASDAI, BASFI and spinal pain, and 181 for ASDAS.

BASDAI, Bath ankylosing spondylitis disease activity index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASFI, Bath AS functional index.

 

 


Disclosure: S. Zhao, None; D. Thong, None; S. Duffield, None; D. Hughes, None; N. Goodson, None.

To cite this abstract in AMA style:

Zhao S, Thong D, Duffield S, Hughes D, Goodson N. The Effect of Alcohol on Disease Activity in Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-effect-of-alcohol-on-disease-activity-in-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-alcohol-on-disease-activity-in-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology